# Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

> **NCT06383533** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Bile Duct Adenocarcinoma Non-Resectable
- HER2 Gene Mutation

## Interventions

- **DRUG:** Disitamab Vedotin Plus Cadonilimab

## Key facts

- **NCT ID:** NCT06383533
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06383533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06383533, "Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06383533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*